Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-23-006265
Filing Date
2023-04-20
Accepted
2023-04-20 07:03:32
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A tmb-20230419xdefa14a.htm DEFA14A 16308
2 GRAPHIC tmb-20230419xdefa14a_bg001.jpg GRAPHIC 159999
3 GRAPHIC tmb-20230419xdefa14a_bg002.jpg GRAPHIC 121841
  Complete submission text file 0001558370-23-006265.txt   405660
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37581 | Film No.: 23831384
SIC: 2834 Pharmaceutical Preparations